This study is registered with, number NCT01394952.īetween Aug 18, 2011, and Aug 14, 2013, 9901 participants (mean age 66♲ years, median HbA 1c 7♲%, 4589 women) were enrolled and randomly assigned to receive dulaglutide (n=4949) or placebo (n=4952). The primary outcome was the first occurrence of the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (including unknown causes), which was assessed in the intention-to-treat population. Participants were followed up at least every 6 months for incident cardiovascular and other serious clinical outcomes. All investigators and participants were masked to treatment assignment. Randomisation was done by a computer-generated random code with stratification by site. Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1♵ mg) or placebo.

This multicentre, randomised, double-blind, placebo-controlled trial was done at 371 sites in 24 countries.

We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of glycaemic control. Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A 1c (HbA 1c) concentrations.

Alejandra costamagna pdf